Credit Suisse raised its price target on Esperion to $130 from $100 citing the company's phase 2b study of ETC-1002, which met its primary endpoints. The firm has an Outperform rating on the shares.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here